Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Roflumilast Tablets, 250 mcg (USRLD: Daliresp Tablets, 250 mcg).
Roflumilast reduces inflammation in the lungs that leads to chronic obstructive pulmonary disease (COPD). It is used to prevent worsening of symptoms in people with severe COPD. The drug will be manufactured at the group’s formulation manufacturing facility in SEZ Ahmedabad, (India).
Roflumilast Tablets, 250 mcg had annual sales of USD 34 mn in the United States (IQVIA MAT Feb. 2023).
The group now has 363 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
Bombay HC: 'Larger Flat Owners Must Pay Higher Maintenance In Condominiums Under 1970 Act'
Mumbai News: BMC Backs Adani's Bandra Reclamation Project, Says Plot Outside CRZ; Petitioner Alleges MSRDC Suppressed Facts
Mumbai News: Animal Feeder Serves Legal Notice To DCP & ACP Over Mulund Police Inaction In Puppy Hit-And-Run FIR
Mumbai News: Public Outrage Over BMC Plan To Demolish Veer Savarkar Flyover In Goregaon For Versova-Dahisar Link Road, Just 7 Years After Construction
